KDR and neoplasm: Another surprising and quite sobering example is Cabozantinib, an oral inhibitor of Tyrosine Kinases including MET and VEGFR2, two major drivers of malignant progression in several neoplasia (41–47), which did not guarantee an OS advantage in patients with PCa (48).